Resultados de la búsqueda 431-440 of 13755 for Raynaud phenomenon
Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these ...
Suwanwela NC. Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis. https://www.uptodate.com/contents/search. Accessed Dec. 27, ...
A biomarker is a measurable indicator of the severity or presence of disease state. Information collected in this study may help doctors to develop new ...
The primary purpose of this study is to create a Mayo Clinic repository for neurodegenerative disorders such as Parkinson's disease (PD), ...
The goal of this research is to investigate the hypothesis that this presentation represents a spatially limited form of CNS inflammatory demyelinating disease.
Detection of Vascular and Inflammatory Plasma Biomarkers in Patients Diagnosed with Obstructive Sleep Apnea and MRI-defined Cerebral Small Vessel Disease.
ADPKD is a leading cause of end-stage renal disease. Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD.
Mayo Clinic Cardiovascular Disease Biobank. Rochester, Minn. The purpose of this study is to determine the innate immune, cell death and oxidative stress ...
... syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke. A ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?